Market Analysis of Penicillin And Cephalosporin Raw Materials
Penicillin products have repeatedly made headlines in the past two years. Amoxicillin has been repeatedly rising throughout the past year. Although the process has been bumpy, it is still not discouraged. Finally, the hard work pays off. Start to shake. The price of penicillin potassium industrial salt is also very strong recently. What is the trend in the later period? Asia Pacific Trading and Data Analysis Center will continue to pay attention.
Amoxicillin, shock adjustment, a resurgence, the market price is around 240, the market inquiry is positive.
Amoxicillin-clavulanate potassium, price stable
Amoxicillin sodium, a slight shock 521
Ampicillin, ampicillin sodium, run smoothly, ampicillin 256, ampicillin sodium about 300
Penicillin sodium (potassium), penicillin sodium, the trend is strong, the market price is 178, the price of penicillin potassium industrial salt is fluctuating, the recent momentum is strong, the quotation range is around 120-135.
Ceftiofur sodium and ceftiofur hydrochloride, the demand is weak, the upward support power is insufficient, the supply of ceftiofur sodium 2220 and ceftiofur hydrochloride is low, and the market price is 1525.
Cefquinoxime sulfate, price fluctuation adjustment, market price 6720
Looking for chemical products? Let suppliers reach out to you!
2026-06-19
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Analysis of The Veterinary Drug Raw Material Market in the 21st Week
-
The world's first iron carrier cephalosporin drug is approved in the EU
-
Over 100 Foreign Pharma Executives Join Chinese Firms in 5 Years Industry Faces Key Challenges
-
Merck’s New CMV Drug Approved in China Targets Nearly 40000 HSCT Patients
-
FDA Approves Datopotamab Deruxtecan for Second Indication 45 Percent Response Rate in EGFR Mutant Lung Cancer
-
UK Parliament Approves Assisted Dying Bill 7500 Could Seek Euthanasia Annually
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
Recommend Reading
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
Mounjaro Usage Doubles in June Sales Surge by 18 in India
-
AstraZeneca to Invest $2 Billion in New U.S. Biologics Facilities
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Downstream Demand Lacks; DMF Market Rides Narrowly on a Weak Note
-
This week, the cyclohexane market in China mainly maintained a stable operation (10.20-10.27)
-
Cost Decline, Weak Demand—Oxynol Prices Fluctuate and Fall This Week
-
October Adipic Acid Market Weakens and Falls
-
EFSA Confirms Safety of Five Food Enzymes from Genetically Modified Strains